Relationship Between Serum Apolipoprotein Levels and Weight Loss in Patients Undergoing Sleeve Gastrectomy for Morbid Obesity

NCT07325916 | Active Not Recruiting

• 1 other identifier: 2024-KAEK-11 134
• Study Type: observational
• Target: 110
• Locations: 1 country
• Sites: 1

Brief Summary

The study looks at whether a specific protein in the blood, called apolipoprotein, can predict how much weight a person might lose after sleeve gastrectomy, a surgery for people with severe obesity. We want to find a specific level of this protein that shows which patients are most likely to lose weight successfully after surgery. By identifying this level, we hope to guide doctors in deciding who should have the surgery and who might do better with non-surgical weight loss methods.

Conditions

Morbid Obesity Requiring Bariatric Surgery

Keywords

morbid obesity; serum apolipoproteins; apolipoprotein AI; apolipoprotein AII; apolipoprotein B100; apolipoprotein CII; apolipoprotein CIII; apolipoprotein D; apolipoprotein E; apolipoprotein E4; apolipoprotein H; apolipoprotein J; apolipoprotein M; sleeve gastrectomy; bariatric surgery

Outcome Measures

Primary Outcomes (1)

• Change in body mass index at 8 months

  8 months after surgery

Secondary Outcomes (1)

• Change in lipid profile at 8 months

  8 months after surgery

Study Arms (1)

Sleeve Gastrectomy Patients

Patients who meet inclusion criteria for the study undergoing sleeve gastrectomy

Procedure: Laparoscopic Sleeve Gastrectomy

Interventions

Laparoscopic Sleeve Gastrectomy PROCEDURE

Laparoscopic Sleeve Gastrectomy

Sleeve Gastrectomy Patients

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients applying to Başakşehir Çam Sakura City Hospital General Surgery Clinic for bariatric surgery

You may qualify if:

• Patients aged 18 to 75
• International Classification of Diseases (ICD) code E66 diagnosis (obesity)
• Patients who have given consent for sleeve gastrectomy
• Patients who are suitable for general anesthesia

You may not qualify if:

• Patients who did not give consent to be included in the study
• Patients who are scheduled for surgery other than sleeve gastrectomy

Sponsors & Collaborators

• Yigit DUZKOYLU: lead

Study Sites (1)

Basaksehir Cam and Sakura City Hospital

Istanbul, Basaksehir, 34480, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood will be centrifuged and serum will be stored separately in eppendorf tubes.

MeSH Terms

Conditions

Obesity, Morbid

Condition Hierarchy (Ancestors)

Obesity; Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: December 24, 2025
• First Posted: January 8, 2026
• Study Start: May 1, 2025
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: January 8, 2026

Record last verified: 2025-12

Locations

TU (1)